Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
December 2025: Ascletis Pharma announced that ASC30, an oral small-molecule GLP-1 receptor agonist, demonstrated 7.7% placebo-adjusted weight loss in a 13-week U.S
In such cases, starting an oral GLP-1 medication may reduce hesitation and improve early engagement with therapy
The amount varies from person to person, but studies have reported average systolic blood pressure reductions of approximately 7 to 11 mmHg
Retatrutides GI effects can cause fluid losses through diarrhea or vomiting
Growth Hormone & IGF Research, 16 (2), 132-142
US$ 21.93
US$ 21.80
US$ 26.89
![3-BEARS [13] CAT](https://cdn.shopify.com/s/files/1/0852/5253/8682/files/3-BEARS_13.webp?v=1703503150)